SLL
Advertisement
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
A fixed-duration venetoclax (Ven)-based regimen is considered a standard of care (SOC) option for patients with ...
The introduction of novel agents has given patients with chronic lymphocytic leukemia (CLL) and small lymphocytic ...
A combination regimen consisting of duvelisib and venetoclax was well tolerated, clinically active, and led to ...
Certain genomic abnormalities are predictive of poor outcomes in chemoimmunotherapy (CIT) in patients with chronic ...
The U.S. Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) in combination with Rituxan® (rituximab) ...
The U.S. Food and Drug Administration (FDA) granted supplemental approval to Calquence® (acalabrutinib) for adults with ...
The U.S. Food and Drug Administration approved ibrutinib in combination with obinutuzumab for ...
The Food and Drug Administration (FDA) approved duvelisib (COPIKTRA) to treat adult patients with relapsed or ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.